| Edmund Krasinski Jr, DO | |
|
6879 N Oracle Rd, Suite 133, Tucson, AZ 85704-4284 | |
| (520) 531-0600 | |
| (520) 531-1190 |
| Full Name | Edmund Krasinski Jr |
|---|---|
| Gender | Male |
| Speciality | Osteopathic Manipulative Medicine |
| Experience | 36 Years |
| Location | 6879 N Oracle Rd, Tucson, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235166984 | NPI | - | NPPES |
| 184177 | Medicaid | AZ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | 2544 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Northwest Medical Center | Tucson, AZ | Hospital |
| Oro Valley Hospital | Oro valley, AZ | Hospital |
| Entity Name | Edmund Krasinski, Jr., D.o., P.l.l.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245269349 PECOS PAC ID: 5193745495 Enrollment ID: O20051201000446 |
News Archive
A late-breaking clinical trial, known as the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial, to be presented at the American Heart Association Scientific Sessions, November 18, 2013, demonstrates that spironolactone did not reduce the primary outcome of cardiovascular death, heart failure hospitalization, nor surviving a cardiac arrest in patients with heart failure and preserved ejection fraction (pump function). However, spironolactone did reduce the major burden faced by these patients-the risk of repeated hospitalizations for heart failure.
Independent clinical trials, including one conducted at the Scheie Eye Institute at the Perelman School of Medicine, have reported safety and efficacy for Leber congenital amaurosis (LCA), a congenital form of blindness caused by mutations in a gene (RPE65) required for recycling vitamin A in the retina.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, announced the publication of two separate peer-reviewed articles describing preclinical data demonstrating that treatment with ACE-041, an inhibitor of signaling through the activin receptor-like kinase 1 receptor, slows tumor growth and progression by inhibiting angiogenesis.
Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, today announced that it will launch a U.S. $30 million transferable rights offering.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Edmund Krasinski Jr, DO Po Box 36234, Tucson, AZ 85740-6234 Ph: (520) 531-0600 | Edmund Krasinski Jr, DO 6879 N Oracle Rd, Suite 133, Tucson, AZ 85704-4284 Ph: (520) 531-0600 |
News Archive
A late-breaking clinical trial, known as the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial, to be presented at the American Heart Association Scientific Sessions, November 18, 2013, demonstrates that spironolactone did not reduce the primary outcome of cardiovascular death, heart failure hospitalization, nor surviving a cardiac arrest in patients with heart failure and preserved ejection fraction (pump function). However, spironolactone did reduce the major burden faced by these patients-the risk of repeated hospitalizations for heart failure.
Independent clinical trials, including one conducted at the Scheie Eye Institute at the Perelman School of Medicine, have reported safety and efficacy for Leber congenital amaurosis (LCA), a congenital form of blindness caused by mutations in a gene (RPE65) required for recycling vitamin A in the retina.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, announced the publication of two separate peer-reviewed articles describing preclinical data demonstrating that treatment with ACE-041, an inhibitor of signaling through the activin receptor-like kinase 1 receptor, slows tumor growth and progression by inhibiting angiogenesis.
Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, today announced that it will launch a U.S. $30 million transferable rights offering.
› Verified 1 days ago
Dr. Basel Skeif, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 5140 E Glenn St, Tucson, AZ 85712 Phone: 520-838-3540 Fax: 520-325-3526 | |
Dr. David Spencer Hamilton Sr., MD Gastroenterology Medicare: Medicare Enrolled Practice Location: 3601 S 6th Ave, Tucson, AZ 85723 Phone: 520-792-1450 | |
Diana Silva Cantillo, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1230 S Cherrybell Stra, Tucson, AZ 85713 Phone: 520-628-8287 | |
Basel Shoua, M.D Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 2070 W Rudasill Rd Ste 130, Tucson, AZ 85704 Phone: 520-797-4468 Fax: 520-797-4502 | |
Hadil Owaynat, DO Gastroenterology Medicare: Medicare Enrolled Practice Location: 1501 N Campbell Ave Rm 6336, Tucson, AZ 85724 Phone: 520-626-2760 Fax: 520-626-6020 | |
Dr. David M Schwartz, DO Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 6200 N La Cholla Blvd, Tucson, AZ 85741 Phone: 520-469-8011 Fax: 520-469-8021 | |
Kenneth Alex Murachanian, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 6060 N Fountain Plaza Dr Ste 270, Tucson, AZ 85704 Phone: 520-229-2578 |